Navigation Links
Soligenix Reports Third Quarter 2011 Financial Results
Date:11/14/2011

Soligenix cannot assure you that it will be able to successfully develop or commercialize products based on its technology, including orBec®, SGX201, SGX202, SGX203, RiVax™, and LPM™, particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its cash expenditures will not exceed projected levels, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec® for gastrointestinal GVHD include the DSMB's recent determination disclosed in our Form 8-K dated September 15, 2011 recommending that Soligenix stop its confirmatory Phase 3 clinical trial of orBec® in acute GI GVHD and the likelihood that: the FDA will  require that Soligenix conduct additional clinical trials to demonstrate the safety and efficacy of orBec® which will take a significant amount of time and money to complete and positive results leading to regulatory approval cannot be assumed; Soligenix is dependent on the expertise, effort, priorities and contractual obligations of third parties in the clinical
'/>"/>
SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Soligenix Announces Formation of Pediatric Crohns Disease Medical Advisory Board
2. Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD
3. Soligenix Reports Second Quarter 2011 Financial Results and Reviews Accomplishments
4. Soligenix Announces Expansion of Partnership With Sigma-Tau Pharmaceuticals for orBec® in Europe
5. Soligenix Announces Appointment of Jerome Zeldis, MD, PhD and Keith Brownlie, CPA to its Board of Directors
6. Soligenix Appoints Joseph Warusz as Vice President of Administration and Controller
7. Soligenix to Present at 13th Annual BIO CEO & Investor Conference
8. Soligenix Appoints Kevin Horgan, MD, as Chief Medical Officer
9. Soligenix Executes Exclusive License with the University of Colorado for Vaccine Thermostabilization Technology
10. Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury
11. Soligenix Announces Preliminary Results of its Phase 2 Clinical Trial of orBec® in the Prevention of Acute GVHD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015 About ... an X-linked disease, which generally affects the male ... and weakness. The disease is caused due to ... the lack of production of dystrophin (a protein ... The lack of dystrophin weakens muscle function, causes ...
(Date:9/2/2015)... 2, 2015  Array BioPharma Inc. (Nasdaq: ... Officer, Ron Squarer , will present at ... The public is welcome to participate in the ... website.Event: Wells Fargo Securities Healthcare ConferencePresenter: Ron Squarer, ... , 10:20 a.m. Eastern Time Webcast: www.arraybiopharma.com ...
(Date:9/2/2015)... , Sept. 2, 2015 About Chronic ... a malignant condition characterized by increased production of lymphocytes. ... B-lymphocytes and then it can spread to other parts ... later stages because of the slow buildup of the ... malignancy spreads to the spleen, liver, and lymph nodes. ...
Breaking Medicine Technology:Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 2Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 3Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 2Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 3
... Nov. 3, 2010 DURECT Corporation (Nasdaq: DRRX ... September 30, 2010. Total revenues were $8.1 million for the ... for the three months ended September 30, 2009; revenues in ... of certain excipients used in REMOXY® to King Pharmaceuticals in ...
... Biotechnology, Inc. (OTC Bulletin Board: CSBR ), a ... tumor specific data to enhance the value of oncology drugs, ... Qualifying Therapeutic Discovery Project ("QTDP"). The QTDP was enacted as ... 2010. About Champions Biotechnology, Inc. Champions Biotechnology, ...
Cached Medicine Technology:DURECT Corporation Announces Third Quarter 2010 Financial Results 2DURECT Corporation Announces Third Quarter 2010 Financial Results 3DURECT Corporation Announces Third Quarter 2010 Financial Results 4DURECT Corporation Announces Third Quarter 2010 Financial Results 5DURECT Corporation Announces Third Quarter 2010 Financial Results 6DURECT Corporation Announces Third Quarter 2010 Financial Results 7Champions Biotechnology Awarded $1.46 million in Grants 2
(Date:9/3/2015)... ... September 03, 2015 , ... ... by connecting accredited and institutional investors to real estate investment opportunities nationwide, today ... meet demand from both investors and sponsoring real estate companies. , ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... Girl’s Night ... at the beautiful Morning Glory Farm, 6205 Kate Road in Monroe, North Carolina. ... event is a corporate or social function, Kate Clyde’s offers off-premise catering and event ...
(Date:9/3/2015)... (PRWEB) , ... September 03, ... ... Washington, a leading provider of comprehensive eating disorder treatment for adults and ... today that Ileana Calinoiu, MD has joined the medical treatment team. As ...
(Date:9/3/2015)... ... September 03, 2015 , ... According to an Oncology Nurse Advisor article ... help patients with oropharyngeal cancer (oral cancer) to be successfully diagnosed and treated for ... by HPV infections, which have a high rate of success in treatment and elimination ...
(Date:9/3/2015)... ... September 03, 2015 , ... Atlantic Information Services, ... “Proven Pharmacy Benefit Strategies for a Rapidly Changing Marketplace.” In this Sept. 16 ... Milliman, will discuss how plan sponsors are adopting bold, innovative strategies to control ...
Breaking Medicine News(10 mins):Health News:RealtyShares Announces Mezzanine Financing Products 2Health News:RealtyShares Announces Mezzanine Financing Products 3Health News:Girl’s Night Out, with Food From Kate Clyde's Catered Creations, to Benefit Core Compassion Project 2Health News:Ileana Calinoiu, MD Joins Eating Recovery Center of Washington Medical Treatment Team 2Health News:Ileana Calinoiu, MD Joins Eating Recovery Center of Washington Medical Treatment Team 3Health News:LA Periodontists Discuss Study on Post-Treatment Oral Rinses Used to Test Recurrence of Oral Cancers 2Health News:LA Periodontists Discuss Study on Post-Treatment Oral Rinses Used to Test Recurrence of Oral Cancers 3Health News:Speakers for Upcoming AIS Virtual Conference on Pharmacy Benefit Strategies Include Executives from CVS Health, Express Scripts 2
... Oracle Healthcare,Acquisition Corp. (the "Company") (OTC Bulletin Board: ... agreement with Precision Therapeutics,Inc. ("PTI") providing for the ... dated as of December 3, 2007 and amended ... amended, the "Merger Agreement"), by and among the,Company, ...
... March 4 ,Cathedral Healthcare System Inc. has agreed ... to settle allegations that it defrauded the federal,Medicare ... settlement resolves allegations that the Newark, N.J.-based,hospital system ... obtain enhanced reimbursement from the federal health care ...
... of veterinary medicine at Iowa State University, has identified ... disease, Immune-Mediated Retinopathy, or IMR, causes loss of function ... canines. , Grozdanic,s findings are published in the March ... Practice. , IMR is very similar to a previously ...
... York man was,charged today in federal court with obstruction ... Warren T. Bamford, Special,Agent in Charge of the Federal ... Agent in Charge of the Department of Health and,Human ... in Charge of the Defense Criminal Investigative Service; Mark,Dragonetti, ...
... 4 Secretary of Health Dr.,Calvin B. Johnson ... in Warren to discuss Governor Edward G. Rendell,s ... the hundreds of thousands of,uninsured adults through his ... insurance is critical to help prevent disease,successfully manage ...
... March 4 Osteotech, Inc.,(Nasdaq: OSTE ), ... solutions for,regenerative medicine, announced today that it has ... to distribute,the BMAC(TM) (Bone Marrow Aspirate Concentrate) System. ... distribute the BMAC(TM),System for bone regeneration in orthopedic ...
Cached Medicine News:Health News:Oracle Healthcare Acquisition Corp. and Precision Therapeutics, Inc. Mutually Terminate Merger Agreement; Oracle Healthcare Acquisition Corp. Cancels Special Meeting 2Health News:Cathedral Healthcare System to Pay U.S. $5.3 Million to Resolve Allegations Involving Inflated Charges to Obtain Higher Medicare Reimbursement 2Health News:Iowa State University researcher identifies eye disease in canines 2Health News:Thomas Farina, Former Pharmaceutical Company District Manager, Charged With Obstruction of Justice 2Health News:Thomas Farina, Former Pharmaceutical Company District Manager, Charged With Obstruction of Justice 3Health News:Health Secretary Stops in Warren County on Statewide Tour to Call for Action on Health Insurance for All Pennsylvanians 2Health News:Osteotech Signs Agreement To Distribute Harvest Technologies' BMAC(TM) System 2Health News:Osteotech Signs Agreement To Distribute Harvest Technologies' BMAC(TM) System 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: